Phaseline

Targets › EML4

EML4 (Echinoderm microtubule-associated protein-like 4): drug programs, companies and trials

6 programs from 5 companies in 48 trials: 26 Phase 2, 11 Phase 1, 6 Phase 3, 5 Phase 4; Oncology; next expected readout Jan 2027.

Essential for the formation and stability of microtubules (MTs). Required for the organization of the mitotic spindle and for the proper attachment of kinetochores to MTs. (UniProt, Q9HC35)

Open in Phaseline: the race on EML4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisCeritinib (LDK378)
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor
ALK, EML4, NPM1Phase 4ALK Positive Malignancies; ALK-positive NSCLC; Neuroblastoma; ALK Positive …Apr 2027
Pfizercrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 4NSCLCMar 2028
PfizerLorlatinib (PF-06463922)
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
ALK, EML4Phase 4Non-Small-Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Ganglioneuroblastoma; Non Small Cell Lung Cancer …Dec 2028
IDEAYA BiosciencesCrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 3Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma …Jan 2027
RocheAlectinib
ALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; EML4-ALK inhibitor
ALK, RET, EML4Phase 3Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Solid Tumors; ALK Fusion-positive Solid or CNS Tumors …Jan 2027
CStone PharmaceuticalsLorlatinib
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
ALK, EML4Phase 2Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMay 2027

Conditions

Advanced Lymphoma (4) Non-small Cell Lung Cancer (3) Carcinoma, Non-Small-Cell Lung (3) Non Small Cell Lung Cancer (3) Metastatic Colorectal Cancer (2) Non-Small Cell Lung Cancer (2) Haematological Malignancy (2) Non Small Cell Lung Cancer Metastatic (2) Uveal Melanoma (1) Metastatic Uveal Melanoma (1) ALK Gene Rearrangement (1) Lung Cancer Stage III (1)

Modalities

small molecule (5), mixed (1)

Companies

Pfizer (2) IDEAYA Biosciences (1) Roche (1) CStone Pharmaceuticals (1) Novartis (1)

Related targets

ALK (6) NPM1 (3) MET (2) ROS1 (2) RET (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.